6945-36-4 Usage
Uses
Used in Pharmaceutical Industry:
4-HYDROXYIMINO-PENTANOIC ACID is used as a therapeutic agent for its potential in treating inflammatory and neurological disorders. Its role in immune response modulation, neuroprotection, and oxidative stress reduction makes it a promising candidate for developing treatments for these conditions.
Used in Neuroprotection:
4-HYDROXYIMINO-PENTANOIC ACID is used as a neuroprotective agent due to its involvement in the synthesis of the neurotransmitter GABA, which plays a crucial role in reducing neuronal excitability and preventing neuronal damage.
Used in Oxidative Stress Reduction:
4-HYDROXYIMINO-PENTANOIC ACID is used as an antioxidant to help reduce oxidative stress, which is implicated in various diseases and aging processes.
Used in Age-Related Cognitive Decline Prevention:
4-HYDROXYIMINO-PENTANOIC ACID is used as a preventive agent for age-related cognitive decline, potentially contributing to maintaining cognitive function and delaying the onset of neurodegenerative diseases.
Used in Diagnostics:
4-HYDROXYIMINO-PENTANOIC ACID is used as a biomarker in the diagnosis and monitoring of certain health conditions, providing valuable information for early detection and treatment planning.
Check Digit Verification of cas no
The CAS Registry Mumber 6945-36-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,4 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 6945-36:
(6*6)+(5*9)+(4*4)+(3*5)+(2*3)+(1*6)=124
124 % 10 = 4
So 6945-36-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H9NO3/c1-4(6-9)2-3-5(7)8/h9H,2-3H2,1H3,(H,7,8)/b6-4-
6945-36-4Relevant academic research and scientific papers
Acyl acid derivative and preparation method and medical application thereof
-
Paragraph 0443-0446, (2020/07/02)
The invention relates to an acyl acid derivative as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and the invention also relates to a use thereof as an active ingredient in the prevention and/or treatment of muscle atrophy-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, senile muscle atrophy, neurogenic muscle atrophy, and a use in the prevention and/or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging, wherein the definition of each group in the general formula (I) is the same as the definition in the specification.
Evaluation of hadacidin analogues
Tibrewal, Nidhi,Elliott, Gregory I.
supporting information; experimental part, p. 517 - 519 (2011/02/25)
Several derivatives of hadacidin have been developed and evaluated for activity against adenylosuccinate synthetase.
